ArticleJournal of pain research2012
Breakthrough cancer pain - still a challenge.
Article in Journal of pain research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 39 citations in OpenAlex.
- SEOM clinical guideline for treatment of cancer pain (2017).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2018Guideline
- The Impact of Massage Therapy on Function in Pain Populations-A Systematic Review and Meta-Analysis of Randomized Controlled Trials: Part II, Cancer Pain Populations.Pain medicine (Malden, Mass.) · 2016Pooled it
- The efficacy of oral piroxicam fast-dissolving tablets versus sublingual fentanyl in incident breakthrough pain due to bone metastases: a double-blinded randomized study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2019Trial
- Compliance with the breakthrough cancer pain European guidelines and impact on patients' quality of life: an observational prospective study.Frontiers in pain research (Lausanne, Switzerland) · 2024Article
- Rapid-Onset Opioids for Management of Breakthrough Cancer Pain: Considerations for Daily Practice.Frontiers in pain research (Lausanne, Switzerland) · 2022Review
- The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.Cancers · 2021Article
- Article
- Breakthrough cancer pain: review and calls to action to improve its management.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Review
- Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets.Drugs in R&D · 2019Article
- Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain.Journal of pain research · 2019Article
- Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm.BMC palliative care · 2018Article
- Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
- Canadian recommendations for the management of breakthrough cancer pain.Current oncology (Toronto, Ont.) · 2016Article
- Review
- Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain.Journal of pain research · 2016Article
- Safety profile of intravenous patient-controlled analgesia for breakthrough pain in cancer patients: a case series study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2014Article
- Single-dose fentanyl sublingual spray for breakthrough cancer pain.Clinical pharmacology : advances and applications · 2013Article
- Breakthrough pain in patients with controlled or uncontrolled basal pain: an observational study.Pain research & managementObservational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breakthrough cancer pain is defined as transient pain exacerbation in patients with stable and controlled basal pain. Although variable, the prevalence of breakthrough cancer pain is high (33%-95%). According to the American Pain Foundation, breakthrough pain is observed in 50%-90% of all hospitalized cancer patients, in 89% of all patients admitted to homes for the elderly and terminal-patient care centers, and in 35% of all ambulatory care cancer patients. The management of breakthrough cancer pain should involve an interdisciplinary and multimodal approach. The introduction of new fentanyl formulations has represented a great advance and has notably improved treatment. Among these, the pectin-based intranasal formulation adjusts very well to the profile of breakthrough pain attacks, is effective, has a good toxicity profile, and allows for convenient dosing - affording rapid and effective analgesia with the added advantage of being easily administered by caregivers when patients are unable to collaborate.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.